https://scholars.lib.ntu.edu.tw/handle/123456789/516779| Title: | Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70-100 mg/dL in Taiwan | Authors: | FANG-JU LIN Shyu, Kou-Gi Hsieh, I-Chang Huey-Herng Sheu, Wayne Tu, Shih-Te Yeh, Shoou-Jeng Chen, Chin-I Lu, Kuo-Cheng Wu, Chia-Chao Shau, Wen-Yi Inocencio, Timothy J Wen, Yao-Chun Yeh, Hung-I |
Keywords: | Coronary artery disease; Cost-effectiveness analysis; Low-density lipoprotein cholesterol; Secondary prevention; Statin;Coronary artery disease; Cost-effectiveness analysis; Low-density lipoprotein cholesterol; Secondary prevention; Statin | Issue Date: | May-2020 | Publisher: | ELSEVIER TAIWAN | Journal Volume: | 119 | Journal Issue: | 5 | Start page/Pages: | 907 | Source: | Journal of the Formosan Medical Association = Taiwan yi zhi | Abstract: | The recommended target low-density lipoprotein cholesterol (LDL-C) level for coronary artery disease (CAD) patients has been lowered from 100 to 70 mg/dL in several clinical guidelines for secondary prevention. We aimed to assess whether initiating statin treatment in CAD patients with baseline LDL-C 70-100 mg/dL in Taiwan could be cost-effective. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/516779 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2020.01.010 | SDG/Keyword: | atorvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; pitavastatin; rosuvastatin; simvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; Article; cardiac patient; cerebrovascular accident; cohort analysis; coronary artery disease; cost effectiveness analysis; drug cost; drug use; gross national product; health care cost; health status; heart infarction; human; incidence; major clinical study; Markov chain; mortality rate; probability; quality adjusted life year; recurrent disease; secondary prevention; sensitivity analysis; Taiwan; coronary artery disease; cost benefit analysis; economics; epidemiology; secondary prevention; Cholesterol, LDL; Coronary Artery Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Quality-Adjusted Life Years; Secondary Prevention; Taiwan [SDGs]SDG3 |
| Appears in Collections: | 臨床藥學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.